· Updated · Venture Capital Tracker · investment-strategies · 3 min read
St. Louis Startups and VC Firms in 2026: Geneoscopy, BioGenerator, Agtech
St. Louis’s venture map in 2026 — Geneoscopy, CoverCress, Allotera Therapeutics, plus BioGenerator Ventures and Cultivation Capital.
St. Louis is a plant-science and biotech corridor — Bayer / Corteva adjacency, WashU / Cortex — with real company pages in our directory. We profile Geneoscopy, CoverCress, and Allotera, plus BioGenerator and Cultivation Capital.
City hub: /vc/st-louis · All cities: /cities · Directory: /directory
What St. Louis is (and is not)
| St. Louis is… | St. Louis is not… |
|---|---|
| Home to Geneoscopy diagnostics and Allotera cell therapy | Empty of local HQ coverage in our directory |
| Strong on BioGenerator company-creation + Cultivation Capital | A complete Benson Hill portfolio (still a gap) |
| Plant-science proof via CoverCress (Bayer majority) | Granular’s HQ city (SF in our data) |
Startups we cover in St. Louis
| Company | What they do | Stage / status | Notable capital | Profile |
|---|---|---|---|---|
| Geneoscopy | Noninvasive colorectal cancer screening (ColoSense) | Growth; Series C $105M (Jan 2025) | — | /startup/geneoscopy |
| Allotera Therapeutics | Allogeneic CAR-T for T-cell malignancies | Growth; ~$115M equity (Aug 2025) | — | /startup/allotera-therapeutics |
| CoverCress | Gene-edited pennycress for low-carbon fuel feedstock | Acquired (Bayer 65%, Aug 2022) | Strategic ag outcome | /startup/covercress |
Why these names matter
Geneoscopy is the diagnostics scale signal — $105M Series C (January 2025) for GI screening. Clinical and reimbursement milestones are the diligence story.
Allotera Therapeutics shows Cortex-class cell therapy capital (~$115M, August 2025).
CoverCress is the plant-science corridor exit/strategic chapter — Bayer majority stake (2022) — not an independent Series B comps slide.
Local investors (St. Louis HQ)
| Firm | Role | Stages / product | Profile |
|---|---|---|---|
| BioGenerator Ventures | Company-creation + early healthcare/ag | Pre-seed / seed | /fund/biogenerator |
| Cultivation Capital | STL early-stage multi-fund platform | Seed / early | /fund/cultivation-capital |
National capital that serves St. Louis (by thesis)
| Firm | Fit for STL founders | Profile |
|---|---|---|
| Khosla Ventures | Food/ag, climate, deep tech | /fund/khosla-ventures |
| ARCH Venture Partners | Biotech company-building from research | /fund/arch-venture-partners |
| F-Prime Capital | Healthcare / life sciences | /fund/f-prime-capital |
| Lux Capital | Deep tech / industrials | /fund/lux-capital |
| General Catalyst | Multi-stage climate and enterprise | /fund/general-catalyst |
Local seed vs national Series A — what differs
| BioGenerator / Cultivation | National growth / specialist | |
|---|---|---|
| Best for | Spinouts, first institutional check | Scaling diagnostics or cell therapy |
| What they underwrite | Science + Midwest GTM | Clinical/regulatory milestones |
| Mistake | Calling CoverCress an independent late-stage peer | Waiting for Benson Hill pages before raising |
Worked example (illustrative)
Setup: A Cortex diagnostics startup closes a BioGenerator creation check and hits clinical validation milestones.
Move: They raise a $50–100M+ specialist round (Geneoscopy-class) once FDA/reimbursement path is clear.
Punch: Science milestones were the diligence artifacts — not a local multi-stage mega-fund in our whitelist.
When St. Louis is the wrong capital market
- You cite CoverCress as an independent growth comps without noting Bayer.
- You invent Benson Hill
/startup/pages we list as gaps. - You refuse clinical/field-trial proof and still expect coastal biotech terms.
- You re-home SF agtech (e.g. Granular) as STL HQ.
How to use this page
- Read Geneoscopy, Allotera, CoverCress.
- Formation: BioGenerator, Cultivation Capital.
- Specialist capital: national table → /directory.
- Hub: /vc/st-louis.
Related reading
Sources
- Venture Capital Tracker profiles linked above
- Geneoscopy Series C (Jan 2025, $105M); Allotera equity financing (Aug 2025, ~$115M); CoverCress Bayer majority (Aug 2022)
- st-louis
- missouri
- venture-capital
- +2 more
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
